These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 21411796)

  • 1. Effect of requiring advance approval of chemotherapy on number and cost of ungiven doses.
    Berhoune M; Aboudagga H; Jacob A; Grandhaye JP; Dayot C; Prognon P; Bonan B
    Am J Health Syst Pharm; 2011 Apr; 68(7):557-8. PubMed ID: 21411796
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cost of functioning of a centralised pharmaceutical unit: evaluation of mean costs of chemotherapy preparations according to the level of production of the unit].
    Galy G; Bauler S; Buchi M; Pirot F; Pivot C
    Bull Cancer; 2011 Oct; 98(10):1153-63. PubMed ID: 22001702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investors buying compounders. Drug shortages are persisting, leading to the deals.
    Lee J
    Mod Healthc; 2013 Jan; 43(3):12-3. PubMed ID: 23487975
    [No Abstract]   [Full Text] [Related]  

  • 4. [Costs of a cytostatic drug preparation unit in a hospital in Mexico].
    Martínez Rodríguez OA; Rivas Bocanegra RE; Ascencio-Pérez IS; Zapata Sánchez LA
    Farm Hosp; 2007; 31(6):375-8. PubMed ID: 18348668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The high cost of customization: compounding drugs.
    Cohen MR
    Hosp Pharm; 1991 Apr; 26(4):384-5. PubMed ID: 10113578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of robotic antineoplastic preparation on safety, workflow, and costs.
    Seger AC; Churchill WW; Keohane CA; Belisle CD; Wong ST; Sylvester KW; Chesnick MA; Burdick E; Wien MF; Cotugno MC; Bates DW; Rothschild JM
    J Oncol Pract; 2012 Nov; 8(6):344-9, 1 p following 349. PubMed ID: 23598843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How we do it: shifting MR arthrogram compounding from the fluoroscopy suite to the sterile pharmacy.
    Adams CC; Loewen MJ; Breckenridge IA; Besich-Carter JE; Bush LA
    Skeletal Radiol; 2019 Mar; 48(3):445-448. PubMed ID: 29846755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost analysis of mixing clindamycin and aminoglycosides.
    Abel SR; Olson SM
    Am J Hosp Pharm; 1987 Jun; 44(6):1385-7. PubMed ID: 3618617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Centralized intravenous additive services (CIVAS): the state of the art in 2010.
    Hecq JD
    Ann Pharm Fr; 2011 Jan; 69(1):30-7. PubMed ID: 21296215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dilemmas in compounding for the veterinary teaching hospital.
    Kemp DT
    J Am Vet Med Assoc; 1994 Jul; 205(2):263-7. PubMed ID: 7928595
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost of implementing Veterans Administration directives for handling antineoplastic agents.
    Murphy CP; Goldspiel BR; Koeller J
    Am J Hosp Pharm; 1987 Apr; 44(4):788-91. PubMed ID: 3578312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compounding practices in Iran.
    Goodarzi N; Niknam S; Akbarzadeh T; Gholami K
    Int J Pharm Compd; 2014; 18(2):112-6. PubMed ID: 24881113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Centralized compounding of cytostatics results in better service and lower cost].
    Eklund LH; Juneskans OT; Mellstedt H; Montelius C
    Lakartidningen; 1991 Mar; 88(12):1108-9. PubMed ID: 1901929
    [No Abstract]   [Full Text] [Related]  

  • 14. Society of Hospital Pharmacists of Australia: are you at risk?
    Aust Hosp; 1981 Jul; (54):4-5. PubMed ID: 10254354
    [No Abstract]   [Full Text] [Related]  

  • 15. Accountability and auditing strategies in a newly opened hospital-based outpatient oncology pharmacy.
    Beaubien JM; Habershaw T; Melfi JJ; Gleckman J; Curtis MA
    Am J Health Syst Pharm; 2011 Oct; 68(19):1770, 1775. PubMed ID: 21930632
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of gentamicin premixed admixtures: cost and clinical utility.
    Zarowitz BJ; Owen H; Popovich J; Pancorbo S
    Hosp Pharm; 1987 Mar; 22(3):257-60. PubMed ID: 10311980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness study of closed system transfer devices for the preparation of antineoplastic agents.
    Calzado-Gómez G; Nazco-Casariego GJ; Viña-Romero MM; Gutiérrez-Nicolás F
    Farm Hosp; 2017 Sep; 41(5):575-582. PubMed ID: 28847246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementation and evaluation of a sterile compounding robot in a satellite oncology pharmacy.
    Bhakta SB; Colavecchia AC; Coffey W; Curlee DR; Garey KW
    Am J Health Syst Pharm; 2018 Jun; 75(11 Supplement 2):S51-S57. PubMed ID: 29802179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compliant compounding. Meeting USP 797 pharmacy regulations.
    Lee LD
    Health Facil Manage; 2010 Feb; 23(2):36-9. PubMed ID: 21638948
    [No Abstract]   [Full Text] [Related]  

  • 20. Analyzing captial investments.
    Gray SP
    Hosp Purch Manage; 1980 Sep; 5(9):3-7. PubMed ID: 10309238
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.